SBX — SynBiotic SE Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- €16.00m
- €17.30m
- €3.86m
Annual income statement for SynBiotic SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | GAS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 5.45 | 8.65 | 8.17 | 3.86 |
Cost of Revenue | |||||
Gross Profit | — | 3.71 | 4.79 | 3.57 | 1.51 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.013 | 6.28 | 20.1 | 34.1 | 15.6 |
Operating Profit | -0.013 | -0.834 | -11.5 | -25.9 | -11.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.013 | -0.859 | -13.4 | -26.2 | -11.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.013 | -0.88 | -13.1 | -26 | -11.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.013 | -0.88 | -12.7 | -24.4 | -10.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.013 | -0.88 | -12.7 | -24.4 | -10.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.051 | -0.509 | -2.87 | -3.24 | -1.77 |
Dividends per Share |